Edoxaban tosylate monohydrate (DU-176b)

Description: Edoxaban tosylate monohydrate (DU-176b; DU-176; trade name Lixiana), the tosylate salt of edoxaban which is a marketed anticoagulant drug, is a potent, selective, orally bioavailable and direct factor Xa inhibitor with potential anti-coagulant activity. It inhibits Factor Xa with a Ki of 0.561 nM, and exhibits > 10 000-fold selectivity over thrombin and FIXa. Edoxaban was developed by Daiichi Sankyo and was approved in July 2011 in Japan for prevention of venous thromboembolisms (VTE) following lower-limb orthopedic surgery. It was also approved by the FDA in January 2015 for the prevention of stroke and non–central-nervous-system systemic embolism.

References: J Thromb Haemost. 2008 Sep; 6(9):1542-9.

Related CAS #: 480449-71-6 (tosylate); 480448-29-1 (HCl); 1229194-11-9 (tosylate hydrate); 480449-70-5 (free base)